Global Specialty Generic Drug Market
Global Specialty Generic Drug Market

Specialty Generic Drug Comprehensive Study by Type (Oral, Parenteral, Topical, Injectable, Others.), Application (Cancer, Rheumatoid Arthritis, Hemophilia, H.I.V. Psoriasis, Inflammatory Bowel Disease, Hepatitis C), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2026

Specialty Generic Drug Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Sep 2021 Edition 210 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Specialty Generic Drug Market Overview:
Specialty Generics drugs are one of the fastest growing areas of health care spending. There is no one set definition of specialty drugs, although insurers and other health care payers often characterize them as prescription products requiring extra handling or administration that are used to treat complex disease. High cost can trigger a specialty drug designation. Biologics, or drugs derived from living cells, are often but not always deemed to be specialty drugs.

Growth Drivers
  • Increased Prevalence Of Cancer
  • Rise In Geriatric Population

Roadblocks
  • Intended Use And Side Effects

Opportunities
  • Rise In Number Of Off-Patent Specialty Drugs

Challenges
  • High Price Of Product And Limited Production


Competitive Landscape:
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
Some of the key players profiled in the report are Akorn Inc. (United States), Valeant Pharmaceuticals International Inc. (United States), Mallinckrodt (Ireland), Sun Pharmaceutical Industries Ltd. (India), Sandoz International GmbH (Germany), Mylan N.V. (United States), Endo Pharmaceuticals Inc. (Ireland), Apotex Corp. (Canada), Pfizer Inc. (United States) and Teva Pharmaceuticals USA, Inc. (United States). Considering Market by Distribution Channel, the sub-segment i.e. Retail Pharmacies will boost the Specialty Generic Drug market.

On 2 March 2021 Drug major Lupin has launched Penicillamine tablets, used to treat Wilson's disease, in the US market. The company has launched a generic product in the market after having received approval from the US and Drug Administration (U.S.FDA) earlier. and On 9 March 2021 Indoco Remedies on Teva Pharmaceuticals has launched Brinzolamide ophthalmic suspension used in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma in the United States.

What Can be Explored with the Specialty Generic Drug Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Specialty Generic Drug Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Specialty Generic Drug
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Specialty Generic Drug market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Specialty Generic Drug market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Specialty Generic Drug Manufactures, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Specialty Generic Drug Market?
The Specialty Generic Drug market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in Specialty Generic Drug Market?
Top performing companies in the Global Specialty Generic Drug market are Akorn Inc. (United States), Valeant Pharmaceuticals International Inc. (United States), Mallinckrodt (Ireland), Sun Pharmaceutical Industries Ltd. (India), Sandoz International GmbH (Germany), Mylan N.V. (United States), Endo Pharmaceuticals Inc. (Ireland), Apotex Corp. (Canada), Pfizer Inc. (United States) and Teva Pharmaceuticals USA, Inc. (United States), to name a few.

3. What trending factors would impact Specialty Generic Drug Market growth most?
"High Investment In Pharmaceuticals Industries" is seen as one of major influencing trends for Specialty Generic Drug Market during projected period 2020-2026.

Report Objectives / Segmentation Covered
By Type
  • Oral
  • Parenteral
  • Topical
  • Injectable
  • Others.
By Application
  • Cancer
  • Rheumatoid Arthritis
  • Hemophilia
  • H.I.V. Psoriasis
  • Inflammatory Bowel Disease
  • Hepatitis C
By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence Of Cancer
      • 3.2.2. Rise In Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. High Price Of Product And Limited Production
    • 3.4. Market Trends
      • 3.4.1. High Investment In Pharmaceuticals Industries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Specialty Generic Drug, by Type, Application, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Specialty Generic Drug (Value)
      • 5.2.1. Global Specialty Generic Drug by: Type (Value)
        • 5.2.1.1. Oral
        • 5.2.1.2. Parenteral
        • 5.2.1.3. Topical
        • 5.2.1.4. Injectable
        • 5.2.1.5. Others.
      • 5.2.2. Global Specialty Generic Drug by: Application (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Rheumatoid Arthritis
        • 5.2.2.3. Hemophilia
        • 5.2.2.4. H.I.V. Psoriasis
        • 5.2.2.5. Inflammatory Bowel Disease
        • 5.2.2.6. Hepatitis C
      • 5.2.3. Global Specialty Generic Drug by: Distribution Channel (Value)
        • 5.2.3.1. Retail Pharmacies
        • 5.2.3.2. Hospital Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Specialty Generic Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Specialty Generic Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Akorn Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Valeant Pharmaceuticals International Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mallinckrodt (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sandoz International GmbH (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mylan N.V. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Endo Pharmaceuticals Inc. (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Apotex Corp. (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Teva Pharmaceuticals USA, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Specialty Generic Drug Sale, by Type, Application, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Specialty Generic Drug (Value)
      • 7.2.1. Global Specialty Generic Drug by: Type (Value)
        • 7.2.1.1. Oral
        • 7.2.1.2. Parenteral
        • 7.2.1.3. Topical
        • 7.2.1.4. Injectable
        • 7.2.1.5. Others.
      • 7.2.2. Global Specialty Generic Drug by: Application (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Rheumatoid Arthritis
        • 7.2.2.3. Hemophilia
        • 7.2.2.4. H.I.V. Psoriasis
        • 7.2.2.5. Inflammatory Bowel Disease
        • 7.2.2.6. Hepatitis C
      • 7.2.3. Global Specialty Generic Drug by: Distribution Channel (Value)
        • 7.2.3.1. Retail Pharmacies
        • 7.2.3.2. Hospital Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Specialty Generic Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Specialty Generic Drug: by Type(USD Million)
  • Table 2. Specialty Generic Drug Oral , by Region USD Million (2015-2020)
  • Table 3. Specialty Generic Drug Parenteral , by Region USD Million (2015-2020)
  • Table 4. Specialty Generic Drug Topical , by Region USD Million (2015-2020)
  • Table 5. Specialty Generic Drug Injectable , by Region USD Million (2015-2020)
  • Table 6. Specialty Generic Drug Others. , by Region USD Million (2015-2020)
  • Table 7. Specialty Generic Drug: by Application(USD Million)
  • Table 8. Specialty Generic Drug Cancer , by Region USD Million (2015-2020)
  • Table 9. Specialty Generic Drug Rheumatoid Arthritis , by Region USD Million (2015-2020)
  • Table 10. Specialty Generic Drug Hemophilia , by Region USD Million (2015-2020)
  • Table 11. Specialty Generic Drug H.I.V. Psoriasis , by Region USD Million (2015-2020)
  • Table 12. Specialty Generic Drug Inflammatory Bowel Disease , by Region USD Million (2015-2020)
  • Table 13. Specialty Generic Drug Hepatitis C , by Region USD Million (2015-2020)
  • Table 14. Specialty Generic Drug: by Distribution Channel(USD Million)
  • Table 15. Specialty Generic Drug Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 16. Specialty Generic Drug Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 17. Specialty Generic Drug Online Pharmacies , by Region USD Million (2015-2020)
  • Table 18. South America Specialty Generic Drug, by Country USD Million (2015-2020)
  • Table 19. South America Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 20. South America Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 21. South America Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 22. Brazil Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 23. Brazil Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 24. Brazil Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 25. Argentina Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 26. Argentina Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 27. Argentina Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 28. Rest of South America Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 29. Rest of South America Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 30. Rest of South America Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 31. Asia Pacific Specialty Generic Drug, by Country USD Million (2015-2020)
  • Table 32. Asia Pacific Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 33. Asia Pacific Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 34. Asia Pacific Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 35. China Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 36. China Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 37. China Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 38. Japan Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 39. Japan Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 40. Japan Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 41. India Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 42. India Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 43. India Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 44. South Korea Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 45. South Korea Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 46. South Korea Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 47. Taiwan Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 48. Taiwan Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 49. Taiwan Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 50. Australia Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 51. Australia Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 52. Australia Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 56. Europe Specialty Generic Drug, by Country USD Million (2015-2020)
  • Table 57. Europe Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 58. Europe Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 59. Europe Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 60. Germany Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 61. Germany Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 62. Germany Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 63. France Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 64. France Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 65. France Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 66. Italy Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 67. Italy Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 68. Italy Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 69. United Kingdom Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 70. United Kingdom Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 71. United Kingdom Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 72. Netherlands Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 73. Netherlands Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 74. Netherlands Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 75. Rest of Europe Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 76. Rest of Europe Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 77. Rest of Europe Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 78. MEA Specialty Generic Drug, by Country USD Million (2015-2020)
  • Table 79. MEA Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 80. MEA Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 81. MEA Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 82. Middle East Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 83. Middle East Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 84. Middle East Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 85. Africa Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 86. Africa Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 87. Africa Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 88. North America Specialty Generic Drug, by Country USD Million (2015-2020)
  • Table 89. North America Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 90. North America Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 91. North America Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 92. United States Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 93. United States Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 94. United States Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 95. Canada Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 96. Canada Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 97. Canada Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 98. Mexico Specialty Generic Drug, by Type USD Million (2015-2020)
  • Table 99. Mexico Specialty Generic Drug, by Application USD Million (2015-2020)
  • Table 100. Mexico Specialty Generic Drug, by Distribution Channel USD Million (2015-2020)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Specialty Generic Drug: by Type(USD Million)
  • Table 112. Specialty Generic Drug Oral , by Region USD Million (2021-2026)
  • Table 113. Specialty Generic Drug Parenteral , by Region USD Million (2021-2026)
  • Table 114. Specialty Generic Drug Topical , by Region USD Million (2021-2026)
  • Table 115. Specialty Generic Drug Injectable , by Region USD Million (2021-2026)
  • Table 116. Specialty Generic Drug Others. , by Region USD Million (2021-2026)
  • Table 117. Specialty Generic Drug: by Application(USD Million)
  • Table 118. Specialty Generic Drug Cancer , by Region USD Million (2021-2026)
  • Table 119. Specialty Generic Drug Rheumatoid Arthritis , by Region USD Million (2021-2026)
  • Table 120. Specialty Generic Drug Hemophilia , by Region USD Million (2021-2026)
  • Table 121. Specialty Generic Drug H.I.V. Psoriasis , by Region USD Million (2021-2026)
  • Table 122. Specialty Generic Drug Inflammatory Bowel Disease , by Region USD Million (2021-2026)
  • Table 123. Specialty Generic Drug Hepatitis C , by Region USD Million (2021-2026)
  • Table 124. Specialty Generic Drug: by Distribution Channel(USD Million)
  • Table 125. Specialty Generic Drug Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 126. Specialty Generic Drug Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 127. Specialty Generic Drug Online Pharmacies , by Region USD Million (2021-2026)
  • Table 128. South America Specialty Generic Drug, by Country USD Million (2021-2026)
  • Table 129. South America Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 130. South America Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 131. South America Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 132. Brazil Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 133. Brazil Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 134. Brazil Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 135. Argentina Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 136. Argentina Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 137. Argentina Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 138. Rest of South America Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 139. Rest of South America Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 140. Rest of South America Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 141. Asia Pacific Specialty Generic Drug, by Country USD Million (2021-2026)
  • Table 142. Asia Pacific Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 143. Asia Pacific Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 144. Asia Pacific Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 145. China Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 146. China Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 147. China Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 148. Japan Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 149. Japan Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 150. Japan Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 151. India Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 152. India Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 153. India Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 154. South Korea Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 155. South Korea Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 156. South Korea Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 157. Taiwan Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 158. Taiwan Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 159. Taiwan Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 160. Australia Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 161. Australia Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 162. Australia Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 166. Europe Specialty Generic Drug, by Country USD Million (2021-2026)
  • Table 167. Europe Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 168. Europe Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 169. Europe Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 170. Germany Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 171. Germany Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 172. Germany Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 173. France Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 174. France Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 175. France Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 176. Italy Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 177. Italy Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 178. Italy Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 179. United Kingdom Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 180. United Kingdom Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 181. United Kingdom Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 182. Netherlands Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 183. Netherlands Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 184. Netherlands Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 185. Rest of Europe Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 186. Rest of Europe Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 187. Rest of Europe Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 188. MEA Specialty Generic Drug, by Country USD Million (2021-2026)
  • Table 189. MEA Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 190. MEA Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 191. MEA Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 192. Middle East Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 193. Middle East Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 194. Middle East Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 195. Africa Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 196. Africa Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 197. Africa Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 198. North America Specialty Generic Drug, by Country USD Million (2021-2026)
  • Table 199. North America Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 200. North America Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 201. North America Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 202. United States Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 203. United States Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 204. United States Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 205. Canada Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 206. Canada Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 207. Canada Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 208. Mexico Specialty Generic Drug, by Type USD Million (2021-2026)
  • Table 209. Mexico Specialty Generic Drug, by Application USD Million (2021-2026)
  • Table 210. Mexico Specialty Generic Drug, by Distribution Channel USD Million (2021-2026)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Specialty Generic Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Specialty Generic Drug: by Application USD Million (2015-2020)
  • Figure 6. Global Specialty Generic Drug: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Specialty Generic Drug Share (%), by Country
  • Figure 8. Asia Pacific Specialty Generic Drug Share (%), by Country
  • Figure 9. Europe Specialty Generic Drug Share (%), by Country
  • Figure 10. MEA Specialty Generic Drug Share (%), by Country
  • Figure 11. North America Specialty Generic Drug Share (%), by Country
  • Figure 12. Global Specialty Generic Drug share by Players 2020 (%)
  • Figure 13. Global Specialty Generic Drug share by Players (Top 3) 2020(%)
  • Figure 14. Global Specialty Generic Drug share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Akorn Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Akorn Inc. (United States) Revenue: by Geography 2020
  • Figure 18. Valeant Pharmaceuticals International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Valeant Pharmaceuticals International Inc. (United States) Revenue: by Geography 2020
  • Figure 20. Mallinckrodt (Ireland) Revenue, Net Income and Gross profit
  • Figure 21. Mallinckrodt (Ireland) Revenue: by Geography 2020
  • Figure 22. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 23. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2020
  • Figure 24. Sandoz International GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Sandoz International GmbH (Germany) Revenue: by Geography 2020
  • Figure 26. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 28. Endo Pharmaceuticals Inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 29. Endo Pharmaceuticals Inc. (Ireland) Revenue: by Geography 2020
  • Figure 30. Apotex Corp. (Canada) Revenue, Net Income and Gross profit
  • Figure 31. Apotex Corp. (Canada) Revenue: by Geography 2020
  • Figure 32. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Teva Pharmaceuticals USA, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Teva Pharmaceuticals USA, Inc. (United States) Revenue: by Geography 2020
  • Figure 36. Global Specialty Generic Drug: by Type USD Million (2021-2026)
  • Figure 37. Global Specialty Generic Drug: by Application USD Million (2021-2026)
  • Figure 38. Global Specialty Generic Drug: by Distribution Channel USD Million (2021-2026)
  • Figure 39. South America Specialty Generic Drug Share (%), by Country
  • Figure 40. Asia Pacific Specialty Generic Drug Share (%), by Country
  • Figure 41. Europe Specialty Generic Drug Share (%), by Country
  • Figure 42. MEA Specialty Generic Drug Share (%), by Country
  • Figure 43. North America Specialty Generic Drug Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Akorn Inc. (United States)
  • Valeant Pharmaceuticals International Inc. (United States)
  • Mallinckrodt (Ireland)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Sandoz International GmbH (Germany)
  • Mylan N.V. (United States)
  • Endo Pharmaceuticals Inc. (Ireland)
  • Apotex Corp. (Canada)
  • Pfizer Inc. (United States)
  • Teva Pharmaceuticals USA, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation